🇺🇸 FDA
Patent

US 9765053

Methods of treatment using selective 5-HT2A inverse agonists

granted A61KA61K31/40A61K31/445

Quick answer

US patent 9765053 (Methods of treatment using selective 5-HT2A inverse agonists) held by ACADIA Pharmaceuticals Inc. expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ACADIA Pharmaceuticals Inc.
Grant date
Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/40, A61K31/445, A61K31/55, A61P